Expression of prolyl 4-hydroxylase beta-polypeptide in non-small cell lung cancer treated with Chinese medicines.

Shu-mei Wang; Li-zhu Lin; Dai-han Zhou; Jing-xu Zhou; Shao-quan Xiong

Return

Expression of prolyl 4-hydroxylase beta-polypeptide in non-small cell lung cancer treated with Chinese medicines.

Author: Shu-mei WANG ¹ ; Li-zhu LIN ² ; Dai-han ZHOU ³ ; Jing-xu ZHOU ³ ; Shao-quan XIONG ⁴
Author Information

1. Department of Clinical Teaching and Research, College of Traditional Chinese Medicine, Chongqing Medical University, Chongqing, 401331, China.
2. Department of Oncology, the First Affiliated Hospital of Guangzhou Traditional Chinese Medicine University, Guangzhou, 510405, China. lizhulin903@21cn.com.
3. Department of Oncology, the First Affiliated Hospital of Guangzhou Traditional Chinese Medicine University, Guangzhou, 510405, China.
4. Department of Oncology, the Affiliated Hospital of Chengdu Traditional Chinese Medicine University, Chengdu, 610075, China.
Publication Type:Journal Article
Keywords: Chinese medicine; Yiqi Chutan Formula; prolyl 4-hydroxylase beta polypeptide; unfolded protein response
MeSH: Animals; Blotting, Western; Carcinoma, Non-Small-Cell Lung; drug therapy; genetics; pathology; Cell Line, Tumor; Cell Proliferation; drug effects; Disease Progression; Drugs, Chinese Herbal; pharmacology; therapeutic use; Electrophoresis, Gel, Two-Dimensional; Gene Expression Regulation, Neoplastic; drug effects; Immunohistochemistry; Lung Neoplasms; drug therapy; genetics; pathology; Mice, Inbred C57BL; Peptide Mapping; Peptides; pharmacology; therapeutic use; Prolyl Hydroxylases; genetics; metabolism; Proteomics; RNA, Messenger; genetics; metabolism; Real-Time Polymerase Chain Reaction; Tissue Array Analysis
From: Chinese journal of integrative medicine 2015;21(9):689-696
CountryChina
Language:English
Abstract:
OBJECTIVESTo investigate the role of prolyl 4-hydroxylase beta polypeptide (P4HB) expressed in lung carcinoma and the intervention effect of Yiqi Chutan Formula (, YQCTF).
METHODSLung carcinoma model was established by subcutaneously inoculating LEWIS lung carcinoma cells in C57BL/6J mice. The differential expression of P4HB protein between the YQCTF (3.0 g/kg, gavage, once daily, 21 days) group and the control group was acquired by a 2 fluorescence difference gel electrophoresis (2D-DIGE), verified by Western blotting and identified by matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF/TOF-MS). The expression of P4HB and P4HB mRNA in cultured A549 cells from cisplatin (DDP) 1.5 µg/mL group and 15% serum combined with DDP 1.5 µg/mL group were detected by cellular immunohistochemistry and reverse transcription-polymerase chain reaction, respectively.
RESULTSThe proteomics research discovered that one-third of differential proteins including P4HB were decreased in the YQCTF group (P<0.01). Clinical pathology and tissue microarray studies showed that P4HB expression in lung cancer tissue was stronger than adjacent tissues and normal lung epithelial (P<0.01). In the YQCTF and DDP combined groups, the expression of P4HB and P4HB mRNA in A549 cell were decreased significantly (P<0.01).
CONCLUSIONYQCTF could inhibit the LEWIS lung carcinoma's growth, decrease the expression of P4HB in LEWIS lung carcinoma and A549 cells. YQCTF might take effect through regulating P4HB in endoplasmic reticulum to inhibit the incidence and growth process of lung carcinoma.